Pfizer seeks US emergency authorization for COVID-19 pill
CEO Albert Bourla said in a statement that the pill could drastically cut deaths and hospitalisations. The Biden administration is set to announce that it will order at least 10 million courses of the pill.
CEO Albert Bourla said in a statement that the pill could drastically cut deaths and hospitalizations. The Biden administration is set to announce that it will order at least 10 million courses of the pill.
Pfizer's CEO Albert Bourla said Tuesday that the pharmaceutical giant was seeking expedited authorization from the US Food and Drug Administraton (FDA) for its newly developed pill to fight COVID-19.
ALSO READ: US parents split over COVID vaccines for young children
The company said that the pill had been shown to reduce hospitalizations and deaths by 89% amongst newly-infected high risk patients.
"With more than five million deaths and countless lives impacted by this devastating disease globally, there is an urgent need for life-saving treatment options," Bourla said.
"We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients."
Pfizer is seeking what is known as an emergency use authorization (EUA) on the basis of initial results from a clinical trial comprising hundreds of COVID-19 patients who were not hospitalized but considered at high risk of progression to severe disease.
Biden administration to order millions of doses
The pharmaceutical giant is the second company to ask the FDA for an EUA after German firm Merck made its request a few weeks ago.
Pfizer said that its pill, which is called Paxlovid, led to side effects in one out of five patients, but that they were mild.
Paxlovid treatment takes five days. The company has said it will deliver 180,000 courses of its Paxlovid pill this year and at least 50 million by next year.
President Joe Biden's administration is expected to announce that it is purchasing 10 million courses of the pill, according to The Washington Post. They've already made an order for 3.1 courses of the Merck pill, Molnupiravir.
Given the timeline between application for an EUA and subsequent authorization, the pills could be available to at-risk patients by late this year or early next.
The pills' development has been hailed by experts who see strong COVID-19 treatments, alongside vaccines, as necessary to ending the pandemic.
Catch your daily dose of Fashion, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.